Research ExplorerPublicationsDose-intensive chemotherapy including rituximab is highly ef...

Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients

Standard

Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients. / Xicoy, Blanca; Ribera, Josep-Maria; Müller, Markus; García, Olga; Hoffmann, Christian; Oriol, Albert; Hentrich, Marcus; Grande, Carlos; Wasmuth, Jan-Christian; Esteve, Jordi; van Lunzen, Jan; Del Potro, Eloy; Knechten, Heribert; Brunet, Salut; Mayr, Christoph; Escoda, Lourdes; Schommers, Philipp; Alonso, Natalia; Vall-Llovera, Ferran; Pérez, Montserrat; Morgades, Mireia; González, José; Fernández, Angeles; Thoden, Jan; Gökbuget, Nicola; Hoelzer, Dieter; Fätkenheuer, Gerd; Wyen, Christoph; PETHEMA Group and German HIV Lymphoma Cohort.

In: LEUKEMIA LYMPHOMA, Vol. 55, No. 10, 25.02.2014, p. 2341-2348.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Xicoy, B, Ribera, J-M, Müller, M, García, O, Hoffmann, C, Oriol, A, Hentrich, M, Grande, C, Wasmuth, J-C, Esteve, J, van Lunzen, J, Del Potro, E, Knechten, H, Brunet, S, Mayr, C, Escoda, L, Schommers, P, Alonso, N, Vall-Llovera, F, Pérez, M, Morgades, M, González, J, Fernández, A, Thoden, J, Gökbuget, N, Hoelzer, D, Fätkenheuer, G, Wyen, C & PETHEMA Group and German HIV Lymphoma Cohort 2014, 'Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients', LEUKEMIA LYMPHOMA, vol. 55, no. 10, pp. 2341-2348. https://doi.org/10.3109/10428194.2013.878933

APA

Xicoy, B., Ribera, J-M., Müller, M., García, O., Hoffmann, C., Oriol, A., Hentrich, M., Grande, C., Wasmuth, J-C., Esteve, J., van Lunzen, J., Del Potro, E., Knechten, H., Brunet, S., Mayr, C., Escoda, L., Schommers, P., Alonso, N., Vall-Llovera, F., ... PETHEMA Group and German HIV Lymphoma Cohort (2014). Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients. LEUKEMIA LYMPHOMA, 55(10), 2341-2348. https://doi.org/10.3109/10428194.2013.878933

Vancouver

Xicoy B, Ribera J-M, Müller M, García O, Hoffmann C, Oriol A et al. Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients. LEUKEMIA LYMPHOMA. 2014 Feb 25;55(10):2341-2348. https://doi.org/10.3109/10428194.2013.878933

Bibtex

@article{99e3e373454f425b8dfff5581ffc09db,
title = "Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients",
abstract = "The results of intensive immunochemotherapy were analyzed in human immunodeficiency virus (HIV)-related Burkitt lymphoma/leukemia (BLL) in two cohorts (Spain and Germany). Alternating cycles of chemotherapy were administered, with dose reductions for patients over 55 years. Eighty percent of patients achieved remission, 11% died during induction, 9% failed and 7% died in remission. Four-year overall survival (OS) and progression-free survival (PFS) probabilities were 72% (95% confidence interval [CI]: 62-82%) and 71% (95% CI: 61-81%). CD4 T-cell count < 200/μL and bone marrow involvement were associated with poor OS (hazard ratio [HR] 3.2 [1.2-8.3] and HR 2.7 [1.1-6.6]) and PFS (HR 3.5 [1.3-9.1] and HR 2.4 [1-5.7]), bone marrow involvement with poor disease-free survival (DFS) (HR 14.4 [1.7-119.7] and Eastern Cooperative Oncology Group (ECOG) score > 2 (odds ratio [OR] 11.9 [1.4-99.9]) with induction death. In HIV-related BLL, intensive immunochemotherapy was feasible and effective, but toxic. Prognostic factors were performance status, CD4 T-cell count and bone marrow involvement.",
author = "Blanca Xicoy and Josep-Maria Ribera and Markus M{\"u}ller and Olga Garc{\'i}a and Christian Hoffmann and Albert Oriol and Marcus Hentrich and Carlos Grande and Jan-Christian Wasmuth and Jordi Esteve and {van Lunzen}, Jan and {Del Potro}, Eloy and Heribert Knechten and Salut Brunet and Christoph Mayr and Lourdes Escoda and Philipp Schommers and Natalia Alonso and Ferran Vall-Llovera and Montserrat P{\'e}rez and Mireia Morgades and Jos{\'e} Gonz{\'a}lez and Angeles Fern{\'a}ndez and Jan Thoden and Nicola G{\"o}kbuget and Dieter Hoelzer and Gerd F{\"a}tkenheuer and Christoph Wyen and {PETHEMA Group and German HIV Lymphoma Cohort}",
year = "2014",
month = feb,
day = "25",
doi = "10.3109/10428194.2013.878933",
language = "English",
volume = "55",
pages = "2341--2348",
journal = "LEUKEMIA LYMPHOMA",
issn = "1042-8194",
publisher = "informa healthcare",
number = "10",

}

RIS

TY - JOUR

T1 - Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients

AU - Xicoy, Blanca

AU - Ribera, Josep-Maria

AU - Müller, Markus

AU - García, Olga

AU - Hoffmann, Christian

AU - Oriol, Albert

AU - Hentrich, Marcus

AU - Grande, Carlos

AU - Wasmuth, Jan-Christian

AU - Esteve, Jordi

AU - van Lunzen, Jan

AU - Del Potro, Eloy

AU - Knechten, Heribert

AU - Brunet, Salut

AU - Mayr, Christoph

AU - Escoda, Lourdes

AU - Schommers, Philipp

AU - Alonso, Natalia

AU - Vall-Llovera, Ferran

AU - Pérez, Montserrat

AU - Morgades, Mireia

AU - González, José

AU - Fernández, Angeles

AU - Thoden, Jan

AU - Gökbuget, Nicola

AU - Hoelzer, Dieter

AU - Fätkenheuer, Gerd

AU - Wyen, Christoph

AU - PETHEMA Group and German HIV Lymphoma Cohort

PY - 2014/2/25

Y1 - 2014/2/25

N2 - The results of intensive immunochemotherapy were analyzed in human immunodeficiency virus (HIV)-related Burkitt lymphoma/leukemia (BLL) in two cohorts (Spain and Germany). Alternating cycles of chemotherapy were administered, with dose reductions for patients over 55 years. Eighty percent of patients achieved remission, 11% died during induction, 9% failed and 7% died in remission. Four-year overall survival (OS) and progression-free survival (PFS) probabilities were 72% (95% confidence interval [CI]: 62-82%) and 71% (95% CI: 61-81%). CD4 T-cell count < 200/μL and bone marrow involvement were associated with poor OS (hazard ratio [HR] 3.2 [1.2-8.3] and HR 2.7 [1.1-6.6]) and PFS (HR 3.5 [1.3-9.1] and HR 2.4 [1-5.7]), bone marrow involvement with poor disease-free survival (DFS) (HR 14.4 [1.7-119.7] and Eastern Cooperative Oncology Group (ECOG) score > 2 (odds ratio [OR] 11.9 [1.4-99.9]) with induction death. In HIV-related BLL, intensive immunochemotherapy was feasible and effective, but toxic. Prognostic factors were performance status, CD4 T-cell count and bone marrow involvement.

AB - The results of intensive immunochemotherapy were analyzed in human immunodeficiency virus (HIV)-related Burkitt lymphoma/leukemia (BLL) in two cohorts (Spain and Germany). Alternating cycles of chemotherapy were administered, with dose reductions for patients over 55 years. Eighty percent of patients achieved remission, 11% died during induction, 9% failed and 7% died in remission. Four-year overall survival (OS) and progression-free survival (PFS) probabilities were 72% (95% confidence interval [CI]: 62-82%) and 71% (95% CI: 61-81%). CD4 T-cell count < 200/μL and bone marrow involvement were associated with poor OS (hazard ratio [HR] 3.2 [1.2-8.3] and HR 2.7 [1.1-6.6]) and PFS (HR 3.5 [1.3-9.1] and HR 2.4 [1-5.7]), bone marrow involvement with poor disease-free survival (DFS) (HR 14.4 [1.7-119.7] and Eastern Cooperative Oncology Group (ECOG) score > 2 (odds ratio [OR] 11.9 [1.4-99.9]) with induction death. In HIV-related BLL, intensive immunochemotherapy was feasible and effective, but toxic. Prognostic factors were performance status, CD4 T-cell count and bone marrow involvement.

U2 - 10.3109/10428194.2013.878933

DO - 10.3109/10428194.2013.878933

M3 - SCORING: Journal article

C2 - 24397614

VL - 55

SP - 2341

EP - 2348

JO - LEUKEMIA LYMPHOMA

JF - LEUKEMIA LYMPHOMA

SN - 1042-8194

IS - 10

ER -